Last reviewed · How we verify
Bexagliflozin tablets
Bexagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose levels.
Bexagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose levels. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Bexagliflozin tablets |
|---|---|
| Also known as | Code name: EGT0001442 |
| Sponsor | Theracos |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 (sodium-glucose cotransporter 2) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
SGLT2 inhibitors block the reabsorption of filtered glucose in the proximal tubule of the nephron, allowing excess glucose to be excreted in the urine. This mechanism reduces blood glucose independently of insulin secretion and has additional cardiovascular and renal protective effects. Bexagliflozin is a selective SGLT2 inhibitor developed for type 2 diabetes management.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Polyuria
- Polydipsia
Key clinical trials
- An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension (PHASE2, PHASE3)
- Bexagliflozin Drug/Drug Interaction Study With Digoxin (PHASE1)
- Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin (PHASE1)
- Bexagliflozin Efficacy and Safety Trial (PHASE3)
- Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects (PHASE3)
- Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects (PHASE1)
- Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment (PHASE3)
- A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bexagliflozin tablets CI brief — competitive landscape report
- Bexagliflozin tablets updates RSS · CI watch RSS
- Theracos portfolio CI